An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s

Jose de Leon; Georgios Schoretsanitis; Can Jun Ruan; Carlos De las Cuevas; John M. Kane; Christoph U. Correll

doi:10.1007/s00406-022-01407-7

An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s

Jose de Leon, Georgios Schoretsanitis, Can Jun Ruan, Carlos De las Cuevas, John M. Kane, Christoph U. Correll

Research output: Contribution to journal › Editorial

9 Scopus citations

Original language	English
Pages (from-to)	537-540
Number of pages	4
Journal	European Archives of Psychiatry and Clinical Neuroscience
Volume	272
Issue number	4
DOIs	https://doi.org/10.1007/s00406-022-01407-7
State	Published - Jun 2022

Bibliographical note

Funding Information:
In the last 3 years, GS has served as a consultant for HLS Therapeutics; JMK has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Dainippon Sumitomo, IntraCellular Therapies, Janssen, Lundbeck, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda and Teva. He is a shareholder of LB Pharma, and The Vanguard Research Group; and CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mindpax, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on Data Safety Monitoring Boards for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, LB Pharma and Mindpax. In the last 3 years, C-JR, CDlC and JdL report no conflicts of interest.

Funding Information:
The authors thank Lorraine Maw, M.A. (Mental Health Research Center at Eastern State Hospital), for editorial assistance.

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00406-022-01407-7

Cite this

de Leon, J., Schoretsanitis, G., Ruan, C. J., De las Cuevas, C., Kane, J. M., & Correll, C. U. (2022). An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. European Archives of Psychiatry and Clinical Neuroscience, 272(4), 537-540. https://doi.org/10.1007/s00406-022-01407-7

@article{358d4ed36cfa4950afc0e3b7bec3632d,

title = "An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s",

author = "{de Leon}, Jose and Georgios Schoretsanitis and Ruan, {Can Jun} and {De las Cuevas}, Carlos and Kane, {John M.} and Correll, {Christoph U.}",

note = "Funding Information: In the last 3 years, GS has served as a consultant for HLS Therapeutics; JMK has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Dainippon Sumitomo, IntraCellular Therapies, Janssen, Lundbeck, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda and Teva. He is a shareholder of LB Pharma, and The Vanguard Research Group; and CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mindpax, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on Data Safety Monitoring Boards for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, LB Pharma and Mindpax. In the last 3 years, C-JR, CDlC and JdL report no conflicts of interest. Funding Information: The authors thank Lorraine Maw, M.A. (Mental Health Research Center at Eastern State Hospital), for editorial assistance.",

year = "2022",

month = jun,

doi = "10.1007/s00406-022-01407-7",

language = "English",

volume = "272",

pages = "537--540",

number = "4",

}

de Leon, J, Schoretsanitis, G, Ruan, CJ, De las Cuevas, C, Kane, JM & Correll, CU 2022, 'An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s', European Archives of Psychiatry and Clinical Neuroscience, vol. 272, no. 4, pp. 537-540. https://doi.org/10.1007/s00406-022-01407-7

An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s. / de Leon, Jose; Schoretsanitis, Georgios; Ruan, Can Jun et al.
In: European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, No. 4, 06.2022, p. 537-540.

Research output: Contribution to journal › Editorial

TY - JOUR

T1 - An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s

AU - de Leon, Jose

AU - Schoretsanitis, Georgios

AU - Ruan, Can Jun

AU - De las Cuevas, Carlos

AU - Kane, John M.

AU - Correll, Christoph U.

N1 - Funding Information: In the last 3 years, GS has served as a consultant for HLS Therapeutics; JMK has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Dainippon Sumitomo, IntraCellular Therapies, Janssen, Lundbeck, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda and Teva. He is a shareholder of LB Pharma, and The Vanguard Research Group; and CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mindpax, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on Data Safety Monitoring Boards for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, LB Pharma and Mindpax. In the last 3 years, C-JR, CDlC and JdL report no conflicts of interest. Funding Information: The authors thank Lorraine Maw, M.A. (Mental Health Research Center at Eastern State Hospital), for editorial assistance.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85127625282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127625282&partnerID=8YFLogxK

U2 - 10.1007/s00406-022-01407-7

DO - 10.1007/s00406-022-01407-7

M3 - Editorial

C2 - 35394202

AN - SCOPUS:85127625282

SN - 0940-1334

VL - 272

SP - 537

EP - 540

JO - European Archives of Psychiatry and Clinical Neuroscience

JF - European Archives of Psychiatry and Clinical Neuroscience

IS - 4

ER -

An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this